GeorgiaTuberculosis profile
Population  2015 4 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.16 (0.13–0.19) 3.9 (3.1–4.8)
Mortality (HIV+TB only) 0.055 (0.031–0.085) 1.4 (0.78–2.1)
Incidence  (includes HIV+TB) 4 (3.2–4.8) 99 (80–120)
Incidence (HIV+TB only) 0.26 (0.16–0.38) 6.4 (3.9–9.5)
Incidence (MDR/RR-TB)** 0.98 (0.81–1.1) 25 (20–28)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.14 (0.058–0.21) 1.1 (0.62–1.6) 1.3 (0.68–1.9)
Males 0.21 (0.14–0.27) 2.5 (1.9–3.1) 2.7 (2.1–3.3)
Total 0.34 (0.25–0.43) 3.6 (3.2–4.1) 4 (3.2–4.8)
TB case notifications, 2015  
Total cases notified 3 611
Total new and relapse 3 152
          - % tested with rapid diagnostics at time of diagnosis 64%
          - % with known HIV status 89%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (66–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.05 (0.04–0.07)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 79 3%
          - on antiretroviral therapy 68 86%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  550
(510–600)
Estimated % of TB cases with MDR/RR-TB 12% (11–14) 33% (29–37)  
% notified tested for rifampicin resistance 65% 64% 2 341
MDR/RR-TB cases tested for resistance to second-line drugs   372
Laboratory-confirmed cases MDR/RR-TB: 418, XDR-TB: 66
Patients started on treatment **** MDR/RR-TB: 466, XDR-TB: 62
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 83% 2 862
Previously treated cases, excluding relapse, registered in 2014 69% 509
HIV-positive TB cases, all types, registered in 2014 76% 21
MDR/RR-TB cases started on second-line treatment in 2013 43% 411
XDR-TB cases started on second-line treatment in 2013 21% 70
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 19%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
30% (27–33)
TB financing, 2016  
National TB budget (US$ millions) 17
Funding source: 42% domestic, 44% international, 14% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data